哌拉西林-他唑巴坦与美罗培南治疗头孢曲松不敏感大肠埃希菌或肺炎克雷伯菌血流感染的赢率分析:MERINO试验的事后洞察
该研究对MERINO试验进行事后赢率分析,比较哌拉西林-他唑巴坦与美罗培南治疗头孢曲松不敏感大肠埃希菌或肺炎克雷伯菌血流感染。以全因死亡、微生物学复发和继发感染构建分层复合终点,赢率估计值为0.40(95%CI 0.22-0.71;P=0.002), favoring 美罗培南。作者认为赢率方法在抗菌试验中具有实用性和可行性。
要点
- 赢率分析显示美罗培南优于哌拉西林-他唑巴坦,赢率0.40(95%CI 0.22-0.71;P=0.002)。
- 73.4%的配对因事件比例小而打平,赢比(win odds)为0.79(95%CI 0.68-0.92)。
- 加入住院时间后打平比例降至4.6%,赢率0.77(95%CI 0.60-0.99;P=0.04)。
核心结论
- 赢率方法应用于MERINO试验数据,显示美罗培南优于哌拉西林-他唑巴坦,并说明该方法在抗菌试验中的实用性和可行性。
研究设计与样本
- 对MERINO试验(比较哌拉西林-他唑巴坦与美罗培南)进行事后赢率分析。
主要发现
- 以全因死亡、微生物学复发和继发感染为分层复合终点,赢率估计值为0.40(95%CI 0.22-0.71;P=0.002), favoring 美罗培南。
- 73.4%的配对因事件比例小而打平;赢比(win odds)为0.79(95%CI 0.68-0.92)。
- 加入住院时间后打平比例降至4.6%,赢率估计值为0.77(95%CI 0.60-0.99;P=0.04)。
临床怎么用
- 作者认为赢率方法在抗菌试验中具有实用性和可行性。
局限性
- 73.4%的配对因事件比例小而打平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials of treatments for serious infections commonly use the primary endpoint of all-cause mortality. However, many trial participants survive their infection and this endpoint may not truly reflect important benefits and risks of therapy. The win ratio uses a hierarchical composite endpoint that can incorporate and prioritize outcome measures by relative clinical importance. METHODS: The win ratio methodology was applied post hoc to outcomes observed in the MERINO trial, which compared piperacillin-tazobactam with meropenem. We quantified the win ratio with a primary hierarchical composite endpoint, including all-cause mortality, microbiological relapse, and secondary infection. A win ratio of 1 would correspond to no difference between the 2 antibiotics, while a ratio <1 favors meropenem. Further analyses were performed to calculate the win odds and to introduce a continuous outcome variable in order to reduce ties. RESULTS: With the hierarchy of all-cause mortality, microbiological relapse, and secondary infection, the win ratio estimate was 0.40 (95% confidence interval [CI], .22-.71]; P = .002), favoring meropenem over piperacillin-tazobactam. However, 73.4% of the pairs were tied due to the small proportion of events. The win odds, a modification of the win ratio accounting for ties, was 0.79 (95% CI, .68-.92). The addition of length of stay to the primary composite greatly minimized the number of ties (4.6%) with a win ratio estimate of 0.77 (95% CI, .60-.99; P = .04). CONCLUSIONS: The application of the win ratio methodology to the MERINO trial data illustrates its utility and feasibility for use in antimicrobial trials.
引用
- Hardy M, Harris PNA, Paterson DL, et al. Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial. Clin Infect Dis. 2024. PMID: 38306577. doi:10.1093/cid/ciae050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。